UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Under the Securities Exchange Act of 1934
(Amendment No. __)*
Arena Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
040047 10 2
--------------------------------------------------------------------------------
(CUSIP Number)
November 17, 2004
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed.
[_] Rule13d-1(b)
[X] Rule13d-1(c)
[_] Rule13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 040047 10 2 13G Page 2 of 6 Pages
----- --------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Versant Capital Management LLC
----- --------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
----- --------------------------------------------------------------------------
3 SEC USE ONLY
----- --------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
----- ---------------------------- ----- -------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 1,500,000
OWNED BY ----- -------------------------------------
EACH 6 SHARED VOTING POWER
REPORTING
PERSON WITH 0
----- -------------------------------------
7 SOLE DISPOSITIVE POWER
1,500,000
----- -------------------------------------
8 SHARED DISPOSITIVE POWER
0
----- --------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,500,000
----- --------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* [ ]
----- --------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.7%
----- --------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
OO
----- --------------------------------------------------------------------------
CUSIP No. 040047 10 2 13G Page 3 of 6 Pages
----- --------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Herriot Tabuteau
----- --------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
----- --------------------------------------------------------------------------
3 SEC USE ONLY
----- --------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
American
----- --------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 (See Item 4)
OWNED BY ----- -------------------------------------
EACH 6 SHARED VOTING POWER
REPORTING
PERSON WITH 0 (See Item 4)
----- -------------------------------------
7 SOLE DISPOSITIVE POWER
0 (See Item 4)
----- -------------------------------------
8 SHARED DISPOSITIVE POWER
0 (See Item 4)
----- --------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 (See Item 4)
----- --------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [X]
----- --------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0.0%
----- --------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IN
----- --------------------------------------------------------------------------
CUSIP No. 040047 10 2 13G Page 4 of 6 Pages
ITEM 1(a). Name of Issuer:
Arena Pharmaceuticals, Inc.
ITEM 1(b). Address of Issuer's Principal Executive Offices:
6166 Nancy Ridge Drive
San Diego, CA
ITEM 2(a). Name of Person Filing:
Versant Capital Management LLC
Herriot Tabuteau
ITEM 2(b). Address of Principal Business Office or, if None, Residence:
Versant Capital Management LLC
45 Rockefeller Plaza
Suite 2074
New York, New York 10111
Herriot Tabuteau
c/o Versant Capital Management LLC
45 Rockefeller Plaza
Suite 2074
New York, New York 10111
ITEM 2(c). Citizenship:
See Item 4 of cover pages.
ITEM 2(d). Title of Class of Securities:
Common Stock, $.0001 par value per share (the "Common Stock").
ITEM 2(e). CUSIP Number:
040047 10 2
ITEM 3. If this statement is filed pursuant to Rule 13d-1(b), or
13d-2(b), check whether the person filing is a:
(a) [ ] Broker or Dealer registered under Section 15 of the Exchange
Act.
(b) [ ] Bank as defined in section 3(a)(6) of the Exchange Act.
(c) [ ] Insurance Company as defined in section 3(a)(19) of the
Exchange Act.
(d) [ ] Investment Company registered under section 8 of the
Investment Company Act.
(e) [ ] An investment advisor in accordance with
Rule 13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act;
(j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(c), check
this box. [X]
CUSIP No. 040047 10 2 13G Page 5 of 6 Pages
ITEM 4. Ownership.
(a) Amount beneficially owned:
Versant Capital Management LLC owns an aggregate of 1,500,000
shares of outstanding Common Stock. Herriot Tabuteau is the
managing member of Versant Capital Management LLC and so may
be deemed to beneficially own such shares of Common Stock. Mr.
Tabuteau disclaims such beneficial ownership.
(b) Percent of class:
5.7%, based upon 26,531,496 shares outstanding on October 29,
2004.
(c) Number of shares as to which each such person has:
(i) Sole power to vote or direct the vote: See Item 5 of
cover pages.
(ii) Shared power to vote or direct the vote: See Item 6
of cover pages.
(iii) Sole power to dispose or to direct the disposition
of: See Item 7 of cover pages.
(iv) Shared power to dispose or to direct the disposition
of: See Item 8 of cover pages.
ITEM 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following. [ ]
ITEM 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not Applicable.
ITEM 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding
Company.
Not Applicable.
ITEM 8. Identification and Classification of Members of the Group.
Not Applicable.
ITEM 9. Notice of Dissolution of Group.
Not Applicable.
ITEM 10. Certification
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired
and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the
securities and were not acquired and are not held in
connection with or as a participant in any transaction having
that purpose or effect.
CUSIP No. 040047 10 2 13G Page 6 of 6 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
November 29, 2004
-----------------------------------------
(Date)
VERSANT CAPITAL MANAGEMENT LLC
By: /s/ Herriot Tabuteau
-------------------------------------
Name: Herriot Tabuteau
Title: Managing Member
/s/ Herriot Tabuteau
-----------------------------------------
Herriot Tabuteau
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934,
as amended, the undersigned hereby agree to the joint filing on behalf of each
of them of a statement on Schedule 13G (including amendments thereto) with
respect to the common stock, $0.0001 par value, of Arena Pharmaceuticals, Inc.
and that this Joint Filing Agreement be included as an exhibit to such
statement. This Joint Filing Agreement may be executed in any number of
counterparts, all of which, taken together, shall constitute one and the same
instrument.
IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing
Agreement as of November 29, 2004.
VERSANT CAPITAL MANAGEMENT LLC
By: /s/ Herriot Tabuteau
-------------------------------------
Name: Herriot Tabuteau
Title: Managing Member
/s/ Herriot Tabuteau
-----------------------------------------
Herriot Tabuteau